Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Target Price at $34.00

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been assigned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $34.00.

A number of equities analysts have commented on the company. Robert W. Baird decreased their price target on Karyopharm Therapeutics from $42.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 12th. HC Wainwright lowered Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 16th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC increased its position in Karyopharm Therapeutics by 265.5% during the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock valued at $506,000 after acquiring an additional 543,556 shares during the last quarter. T. Rowe Price Investment Management Inc. bought a new stake in Karyopharm Therapeutics during the first quarter valued at about $523,000. Northern Trust Corp boosted its stake in shares of Karyopharm Therapeutics by 23.5% in the fourth quarter. Northern Trust Corp now owns 283,729 shares of the company’s stock worth $192,000 after acquiring an additional 54,061 shares during the period. Two Sigma Investments LP boosted its stake in shares of Karyopharm Therapeutics by 60.3% in the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock worth $93,000 after acquiring an additional 51,856 shares during the period. Finally, Focus Partners Wealth bought a new position in shares of Karyopharm Therapeutics in the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Down 2.9%

NASDAQ:KPTI opened at $6.08 on Monday. The business’s 50-day moving average price is $5.34 and its two-hundred day moving average price is $5.20. Karyopharm Therapeutics has a twelve month low of $3.51 and a twelve month high of $16.95. The stock has a market cap of $52.71 million, a P/E ratio of -0.42 and a beta of 0.35.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Monday, August 11th. The company reported ($4.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.80) by ($0.52). The company had revenue of $37.93 million during the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).